Cyprotex PLC Installation of two mass spectrometer systems
25 August 2016 - 4:02PM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
25 August 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex install two AB Sciex TripleTOF(R) 6600
mass spectrometer systems
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the installation of two AB
Sciex TripleTOF(R) 6600 mass spectrometer systems. The instruments
will complement our existing Waters Xevo G2-XS QTof mass
spectrometer used for high resolution accurate mass metabolite
identification studies. The TripleTOF(R) technology has several
advantages in that it generates manageable file sizes which allows
more rapid data processing, and has a wider linear dynamic range to
analyse concentrations over 5 orders of magnitude. These features
make the system more appropriate for high throughput ADME
capabilities where rapid analysis of samples from in vitro drug
metabolism studies is required. One of the TripleTOF(R) systems
features an Eksigent MicroLC liquid chromatography system at the
front end, an IonDrive(TM) Turbo V ionisation source, and SWATH
acquisition technology. The Eksigent system uses capillary flow
HPLC with lower flow rates, reduced sample requirements, and
improved ionisation efficiency and sensitivity. The IonDrive(TM)
Turbo V ionisation source and SWATH acquisition technology further
enhance sensitivity. These combined qualities make the system more
suitable for the analysis of large molecule biotherapeutics and the
detection of low levels of metabolites.
One of the TripleTOF(R) systems has been housed at our
Macclesfield site where it will support high throughput ADME
studies, eliminating the need for upfront compound optimisations
required by triple quadrupole mass spectrometer systems, and the
other has been housed at our new bioanalytical laboratory at the
Alderley Park Biohub where it will support lower throughput
metabolite identification studies and large molecule biotherapeutic
analysis.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
"As we expand into new markets, our analytical capabilities need to
diversify to meet the requirements for different types of
molecules. Cyprotex now have an impressive range of analytical
separation and detection capabilities enabling us to tackle more
challenging molecules with the greatest chance of success."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemTarget,
chemPK(TM) and chemTox, and a range of skin, ocular and endocrine
disruption services. For more information, please visit
www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGZRZDMGVZM
(END) Dow Jones Newswires
August 25, 2016 02:02 ET (06:02 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024